Mena H R, Lomen P L, Turner L F, Lamborn K R, Brinn E L
Am J Med. 1986 Mar 24;80(3A):141-4. doi: 10.1016/0002-9343(86)90133-6.
A multi-dose, double-blind, randomized, placebo-controlled, multicenter study was conducted to evaluate 68 patients with acute bursitis or tendinitis following treatment with flurbiprofen (Ansaid, Upjohn) or placebo. Flurbiprofen was administered in a total daily dosage of 200 to 300 mg four times daily. Based on efficacy rating scales, flurbiprofen-treated patients had the greatest proportion of improvement at almost all time periods. They also showed statistically significant improvement compared with placebo-treated patients, according to investigators' overall assessments at all time periods. Most patients showed improvement within three to four days of treatment. Flurbiprofen was both well tolerated and effective for the relief of pain caused by bursitis or tendinitis of the shoulder.
开展了一项多剂量、双盲、随机、安慰剂对照、多中心研究，以评估68例急性滑囊炎或肌腱炎患者接受氟比洛芬（安赛蜜，优普强公司）或安慰剂治疗后的情况。氟比洛芬的每日总剂量为200至300毫克，每日服用四次。根据疗效评定量表，在几乎所有时间段，接受氟比洛芬治疗的患者改善比例最高。根据研究人员在所有时间段的总体评估，与接受安慰剂治疗的患者相比，他们也显示出统计学上的显著改善。大多数患者在治疗三到四天内显示出改善。氟比洛芬对缓解肩部滑囊炎或肌腱炎引起的疼痛耐受性良好且有效。
